SCHEMBL23258199

SCHEMBL23258199

COC(=O)C1CCN(c2nc(CCC=O)cn(COCC[Si](C)(C)C)c2=O)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.36
MAPT P10636 3/20 0.36
TSHR P16473 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
OPRK1 P41145 1/20 0.35
OGFRL1 Q5TC84 1/20 0.35
DGAT1 O75907 3/20 0.35
KDM4E B2RXH2 6/20 0.34
KMT2A Q03164 2/20 0.34
HIF1A Q16665 1/20 0.34
LMNA P02545 1/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
MEN1 O00255 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NEK2 P51955 1/20 0.33
HSD17B10 Q99714 2/20 0.32
HPGD P15428 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26031619 0.91 DGAT1 (0.33) ALDH1A1DGAT1KLKB1
SCHEMBL21552933 0.88 OPRM1 (0.36) ALDH1A1MAPTTSHRNPSR1OPRM1
SCHEMBL21564778 0.86 OPRM1 (0.39) ALDH1A1MAPTTSHRNPSR1OPRM1
SCHEMBL21553059 0.84 DGAT1 (0.31) DGAT1KLKB1
SCHEMBL21552998 0.84 DGAT1 (0.35) ALDH1A1MAPTTSHRNPSR1OPRM1
SCHEMBL21552858 0.84 OPRM1 (0.38) ALDH1A1MAPTTSHRNPSR1OPRM1
SCHEMBL21553037 0.83 ALDH1A1 (0.33) ALDH1A1MAPTDGAT1KDM4EKMT2A
SCHEMBL21564568 0.83 ALDH1A1 (0.33) ALDH1A1MAPTDGAT1KDM4EKMT2A
SCHEMBL21553060 0.83 KLKB1 (0.33) DGAT1KMT2AMEN1KLKB1
SCHEMBL21553013 0.83 MEN1 (0.34) ALDH1A1TSHRDGAT1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A ALDH1A1 839/4885MAPT 4010/4885TSHR 4447/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A ALDH1A1 599/4885MAPT 4054/4885TSHR 4375/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A ALDH1A1 839/4885MAPT 4010/4885TSHR 4447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.